Literature DB >> 11713944

Previous or occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma without hepatic fibrosis.

S Kubo1, A Tamori, K Ohba, T Shuto, T Yamamoto, H Tanaka, S Nishiguchi, K Wakasa, K Hirohashi, H Kinoshita.   

Abstract

We investigated the role of hepatitis B virus infection in development of hepatocellular carcinoma in hepatitis C virus-infected patients without hepatic fibrosis. Of 253 patients, 8 lacked hepatic fibrosis (group 1); group 2 included the remaining 245 patients. Clinicopathologic findings were compared between the groups. Hepatitis B x gene was sought in cancers and adjoining noncancerous liver. Group 1 showed better liver function parameters and milder active hepatitis than group 2. The proportion of patients with anti-hepatitis B virus antibody tended to be higher in group 1 than in group 2. The proportion of patients with hepatitis B x RNA in cancers was significantly higher in group 1 than in group 2. All group 1 patients had previous or occult hepatitis B virus infection. Previous or occult hepatitis B virus infection may be critical in development of hepatocellular carcinomas in hepatitis C virus-infected patients without hepatic fibrosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11713944     DOI: 10.1023/a:1012359400193

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  49 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  HCV-associated hepatocellular carcinoma without cirrhosis.

Authors:  A el-Refaie; K Savage; S Bhattacharya; S Khakoo; T J Harrison; M el-Batanony; S Nasr; N Mokhtar; K Amer; P J Scheuer; A P Dhillon
Journal:  J Hepatol       Date:  1996-03       Impact factor: 25.083

3.  Persistence of hepatitis B viral DNA after serological recovery from hepatitis B virus infection.

Authors:  H E Blum; T J Liang; E Galun; J R Wands
Journal:  Hepatology       Date:  1991-07       Impact factor: 17.425

4.  Frequent detection of hepatitis B virus X-gene DNA in hepatocellular carcinoma and adjacent liver tissue in hepatitis B surface antigen-negative patients.

Authors:  M Takeuchi; J Fujimoto; H Niwamoto; Y Yamamoto; E Okamoto
Journal:  Dig Dis Sci       Date:  1997-11       Impact factor: 3.199

5.  The role of previous infection of hepatitis B virus in Hbs antigen negative and anti-HCV negative Japanese patients with hepatocellular carcinoma: etiological and molecular biological study.

Authors:  Y Matsuzaki; M Sato; Y Saito; M Karube; M Doy; J Shoda; M Abei; N Tanaka; T Hadama; M Kinoshita
Journal:  J Exp Clin Cancer Res       Date:  1999-09

6.  Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan.

Authors:  Y Shiratori; S Shiina; M Imamura; N Kato; F Kanai; T Okudaira; T Teratani; G Tohgo; N Toda; M Ohashi
Journal:  Hepatology       Date:  1995-10       Impact factor: 17.425

7.  The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

Authors:  B Rehermann; C Ferrari; C Pasquinelli; F V Chisari
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

8.  Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma.

Authors:  P Paterlini; K Poussin; M Kew; D Franco; C Brechot
Journal:  Hepatology       Date:  1995-02       Impact factor: 17.425

9.  Hepatitis B virus persistence after recovery from acute viral hepatitis.

Authors:  T I Michalak; C Pasquinelli; S Guilhot; F V Chisari
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

10.  Relationship between multicentric occurrence of hepatocellular carcinoma and histology of noncancerous hepatic tissue in patients with chronic hepatitis C.

Authors:  S Kubo; T Yamamoto; T Ikebe; T Shuto; K Hirohashi; H Tanaka; T Tsukamoto; K Wakasa; H Kinoshita
Journal:  Jpn J Cancer Res       Date:  1999-10
View more
  7 in total

1.  Incidence of transaminitis among HIV-infected patients with occult hepatitis B.

Authors:  Vincent Lo Re; Benjamin Wertheimer; A Russell Localio; Jay R Kostman; Janel Dockter; Jeffrey M Linnen; Cristina Giachetti; Zachariah Dorey-Stein; Ian Frank; Brian L Strom; Robert Gross
Journal:  J Clin Virol       Date:  2008-05-16       Impact factor: 3.168

Review 2.  Clinical impact of occult hepatitis B virus infection in immunosuppressed patients.

Authors:  Evangelista Sagnelli; Mariantonietta Pisaturo; Salvatore Martini; Pietro Filippini; Caterina Sagnelli; Nicola Coppola
Journal:  World J Hepatol       Date:  2014-06-27

Review 3.  Occult HBV infection in the oncohematological setting.

Authors:  C Sagnelli; M Macera; M Pisaturo; R Zampino; M Coppola; E Sagnelli
Journal:  Infection       Date:  2016-04-13       Impact factor: 3.553

Review 4.  Update on occult hepatitis B virus infection.

Authors:  Manoochehr Makvandi
Journal:  World J Gastroenterol       Date:  2016-10-21       Impact factor: 5.742

Review 5.  Hepatitis B virus infection: Defective surface antigen expression and pathogenesis.

Authors:  Chun-Chen Wu; Ying-Shan Chen; Liang Cao; Xin-Wen Chen; Meng-Ji Lu
Journal:  World J Gastroenterol       Date:  2018-08-21       Impact factor: 5.742

6.  Prior hepatitis B virus infection as a co-factor of chronic hepatitis C patient survival after resection of hepatocellular carcinoma.

Authors:  Yutaka Midorikawa; Tadatoshi Takayama; Hisashi Nakayama; Tokio Higaki; Masamichi Moriguchi; Kyoji Moriya; Tatsuo Kanda; Shunichi Matsuoka; Mitsuhiko Moriyama
Journal:  BMC Gastroenterol       Date:  2019-08-19       Impact factor: 3.067

7.  Nondegradable Collagen Increases Liver Fibrosis but Not Hepatocellular Carcinoma in Mice.

Authors:  Jacopo Baglieri; Cuili Zhang; Shuang Liang; Xiao Liu; Takahiro Nishio; Sara B Rosenthal; Debanjan Dhar; Hua Su; Min Cong; Jidong Jia; Mojgan Hosseini; Michael Karin; Tatiana Kisseleva; David A Brenner
Journal:  Am J Pathol       Date:  2021-06-11       Impact factor: 5.770

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.